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Abstract The human ryanodine receptor type 3 (RYR3) was
cloned from a fetal brain cDNA library and its complete
sequence was determined (EMBL accession number AJ001515).
The sequenced cDNA spanned 15 564 bp and contained an open
reading frame of 14 613 bp. The corresponding protein consisted
of 4870 amino acids with a calculated molecular mass of 552
kDa. Amino acid sequence identities to the RYR3 proteins from
rabbit, mink, and chicken were 96%, 95%, and 83% respectively.
A previously unidentified alternative splice site was detected
generating a transcript that lacked bases 11 569^11 650 and
encoded a truncated protein.
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1. Introduction
The release of calcium ions from internal stores such as the
endoplasmic reticulum into the cytoplasm is an important
response to a variety of extracellular stimuli. Two families
of calcium channels have been identi¢ed that mediate this
calcium release: the inositol-1,4,5-trisphosphate receptors
and the ryanodine receptors (RYRs) [1^4]. So far three di¡er-
ent RYR genes have been isolated. RYR1 is the major cal-
cium release channel of the sarcoplasmic reticulum in skeletal
muscle while RYR2 is the corresponding molecule in cardiac
muscle. RYR3, also termed brain-type RYR, is expressed in
speci¢c regions of the brain, i.e. hippocampus, corpus stria-
tum and thalamus. It should be noted that RYR1 and RYR2
are also found in the brain but the expression patterns are
di¡erent for the three subtypes [5]. RYR3 is also expressed in
skeletal muscle but its protein amount is less than 1% of the
amount of RYR1 [6]. So far, the function of RYR3 is unclear.
RYR3 de¢cient mice are viable and fertile and show only
slight behavioral abnormalities [7,8]. The analysis of the pro-
tein function is hampered by the fact that the RYRs are ex-
tremely large proteins which contain approximately 5000 ami-
no acids. Functional calcium release channels are formed by
RYR tetramers and have a molecular mass of more than 2000
kDa.
From the amino acid sequence two models of the protein
structure have been proposed which contain either 4 or 10
transmembrane domains, a large cytoplasmic domain (foot
region) and a very small luminal domain [9,10]. Recent ad-
vances in electron microscopy of 2D crystals have provided an
image of RYR1 molecules at 3 nm resolution. These data are
in favor of the 10 transmembrane model [11].
Full-length RYR3 has been cloned from rabbit, mink, and
very recently from man [12^15]. Beside these mammalian se-
quences the homologous sequences from chicken and bullfrog
have also been determined [16,17]. The channel properties of
rabbit RYR3 were analyzed using native receptors from brain
[18] or recombinant receptors expressed in HEK 293 cells [13].
The diversity of the RYRs is extended by the existence of
multiple splice variants. In RYR3 three alternative splice sites
ASI, ASII, and ASIII have been described which a¡ect a
potential modulatory region between amino acids 3335 and
3710 of the mink sequence [14]. Another alternative splice site
is located in the channel forming region and leads to a trun-
cated protein that lacks the C-terminal 250 amino acids [19].
The distribution of the splice variants of the RYR3 gene
seems to be tissue-speci¢c [14,19].
To investigate the properties of the human RYR3 we have
cloned and sequenced the complete RYR3 cDNA. We were
able to determine a number of polymorphisms and found a
novel alternative splice site.
2. Materials and methods
2.1. Isolation of RYR3 cDNA clones
A random primed fetal brain cDNA library constructed in VZAPII
(Stratagene) was used for the screening of RYR3 clones. The library
was screened six times according to [20] to isolate a total of 20 over-
lapping cDNA clones. For the initial screen we used the following
probes: TIGR/ATCC human cDNA clone HE9MN66 (ATCC
102029, accession number T28322, nucleotide positions 14 386^
15 564, +1 is the A of the start codon) and a RT-PCR product
from pig RNA corresponding to nucleotide positions 1518^2006
[21,22]. All subsequent probes were derived from end fragments of
the isolated clones. In detail, fragments corresponding to the follow-
ing nucleotide positions were used: 3343^3956 and 12 458^12 800 (sec-
ond screen), 9378^9789 (third screen), 7898^8884 (fourth screen),
4922^5430 (¢fth screen), and 4132^5360 (sixth screen).
2.2. Sequencing
Sequencing was performed on plasmid templates either with the T7
Sequencing kit (Pharmacia) and [K-35S]thiodATP as label or with the
Thermo Sequenase kit (Amersham) and a LICOR 4000L automated
sequencer. Both strands of all RYR3 clones were completely se-
quenced using either appropriate subclones or a primer walking strat-
egy. The sequences were analyzed with Sequencher 3.0 and Mac-
DNASIS 3.6.
2.3. RT-PCR
Human fetal brain total RNA pooled from 24 individuals was ob-
tained from Clontech (Cat. No. 64019-1). 75 pmol of 5P-(T)24V-3P was
annealed to 2 Wg of RNA and reverse transcribed with 200 U of
SuperscriptII reverse transcriptase (Gibco-BRL) according to the
manufacturer’s protocol. 2 Wl of this cDNA was used in a 100 Wl
PCR reaction containing 100 pmol of each primer, 200 WM dNTPs,
2 U Taq polymerase (Pharmacia) and the supplied reaction bu¡er.
After an initial denaturation of 5 min at 94‡C, 35 cycles of 1 min
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94‡C, 1 min 55‡C and 2 min 72‡C were performed in a Hybaid
Omnigene thermocycler. RT-PCR products were separated on 1%
agarose gels and cloned into pGEM-4Z for sequencing. Densitometric
analysis of agarose gels was performed with Eagle Sight 3.0 on an
Eagle Eye II (Stratagene) documentation system.
2.4. Primer sequences
The names of the primers indicate their positions on the human
RYR3 cDNA sequence, V: forward, R: reverse. RYR3V2014, 5P-
TTC CTA ACA GCA GAG CC-3P ; RYR3R2307, 5P-GAA GTT
CTC AAA CAT CCC-3P ; RYR3V9984, 5P-TGG AGA CAG CAA
AAG CAA G-3P ; RYR3R11668, 5P-TGC CAT TTA CCA CAT TCC
C-3P ; RYR3V11217, 5P-ACA GTT ACT TTG TGA GGG-3P ;
RYR3R11799, 5P-TGG GTC ATA TTC TTT GAA GG-3P.
3. Results and discussion
3.1. Cloning and sequencing of the human RYR3 cDNA
A random primed fetal brain cDNA library was chosen to
isolate overlapping RYR3 clones. This strategy was employed
instead of RT-PCR to minimize the chance of artifacts due to
polymerase errors during ampli¢cation. To accelerate the
screening of the library we initially used a probe near the 5P
end and a probe containing the 3P end of the RYR3 cDNA.
The 3P probe was available from the TIGR/ATCC special
collection of human cDNA clones, while for the 5P region a
heterologous probe was obtained by RT-PCR on pig RNA.
The ¢rst screening of the library resulted in the isolation of
three phage clones from the 5P end of the RYR3 gene (Fig. 1)
and ¢ve independent phage clones from the 3P end. The clone
RYR3C-11 contained the start codon and at least 70 bp of 5P
untranslated sequence as was determined by comparison with
the rabbit RYR3 sequence. As this clone contained a chimeric
insert it was not possible to specify the exact 5P end of the
RYR3 cDNA. After the ¢rst screening of the library, end
fragments of isolated clones were used as probes for further
screenings of the library. The procedure was repeated ¢ve
times until a total of 20 RYR3 phages had been isolated
which harbored the complete RYR3 cDNA. The positions
of these clones are indicated in Fig. 1. All the RYR3 contain-
ing phages were completely sequenced on both strands. RYR3
containing fragments of chimeric inserts were identi¢ed by
comparison to the rabbit RYR3 sequence.
3.2. Analysis of polymorphisms
Most of the RYR3 cDNA was present on more than one
phage clone. During the sequencing of these clones a number
of nucleotide di¡erences became apparent. A summary of all
these sites is given in Table 1. Remarkably, several of these
nucleotide substitutions also resulted in amino acid exchanges.
This phenomenon could either be due to cloning artifacts or
on the other hand these mutations could represent truly di¡er-
ent alleles. In the latter case one can assume that these amino
acid changes do not severely a¡ect protein function. To test
for the possibility of cloning artifacts, a cDNA fragment lo-
cated at nucleotides 2014^2307 was ampli¢ed by RT-PCR on
human fetal brain RNA pooled from 24 individuals. The am-
pli¢cation product was cloned and several clones were se-
quenced. At both polymorphic sites, i.e. positions 2078 and
2191, both alleles were represented in several clones. There-
fore, it is conceivable that the polymorphisms found are most
likely authentic re£ections of the haplotypes present in the
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Fig. 1. Overview of the isolated RYR3 cDNA clones. The bold line indicates the complete RYR3 cDNA. Thin lines represent isolated RYR3
clones. The clone ATCC 102029 was obtained from ATCC and served as probe for the initial screening of the library. Chimeric parts of the
isolated phages are shown as dotted lines.
Table 1
Nucleotide polymorphisms of the human RYR3 cDNA
Nucleotide position Nucleotide exchange Amino acid exchange
783 TCG S261CR261
1110 CCT silent
1480 ACG I494CV494
2078 GCA C693CY693
2191 GCA V731CI731
4139 ACG E1380CI1380
6803^6805 Deletion of GCA Deletion of S2268
9111 GCA Silent
14 939^14 942 Deletion of ACTC Silent (3P-UTR)
15 356^15 364 (A)9C(A)8 Silent (3P-UTR)
15 453 ACG Silent (3P-UTR)
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population. All the mutations were located in the N-terminal
part of the protein. In the C-terminal part of RYR3, which
contains the channel forming region, no mutation was found
although several independent phage clones from the cDNA
library were sequenced. Apparently in this region of the pro-
tein mutations are less tolerable than in the N-terminal region.
In the 3P untranslated region further nucleotide polymor-
phisms were observed (Table 1). The comparison of our
RYR3 sequence with the human RYR3 sequence of Nakashi-
ma et al. [15] revealed several di¡erences. Most strikingly,
their sequence [15] contained insertions of single G residues
after nucleotides 2224, 2248, and 2298 which led to a frame
shift in this region so that amino acids 742^766 were com-
pletely di¡erent from our sequence which is identical to the
sequences of rabbit, mink and chicken in this region. The
sequence of Nakashima et al. [15] also lacked the 15 bp of
alternative splice site ASI from 10 012^10 026. In addition to
these two di¡erences, 24 nucleotide substitutions were de-
tected that resulted in 15 amino acid exchanges.
3.3. Analysis of splice variants
Alternative splice sites were named according to the nomen-
clature of Marziali et al. [14] who described alternative splice
sites ASI, ASII, and ASIII. The alternative splice site found
by Miyatake et al. [19] was named ASIV.
ASI, ASII, and ASIII are located relatively close together
between positions 10 012 and 11 163 on the human RYR3
cDNA. The use of these alternative splice sites a¡ects the
potential modulatory region of the channel between amino
acid residues 3338 and 3721. To investigate the di¡erent splice
variants within the whole region of ASI, ASII, and ASIII, we
designed PCR primers to amplify this part of the cDNA from
position 9984 to 11 668 by RT-PCR. The ampli¢cation prod-
uct was cloned and several clones were sequenced. The use of
ASI was con¢rmed as approximately 50% of the sequenced
clones lacked the 15 bp at 10 012^10 026. ASII and ASIII,
however, did not seem to be used in human fetal brain as
all sequenced clones contained the 18 bp exon of ASII and
exon B of ASIII.
The sequencing of the RT-PCR products revealed several
clones lacking nucleotides 11 569^11 650. In order to con¢rm
the presence of this novel alternative splice site designated
ASV, a new PCR primer pair was designed that produced a
583 bp product or a 501 bp product depending on the pres-
ence or absence of nucleotides 11 569^11 650. RT-PCR was
performed in two separate experiments and showed that a
signi¢cant portion of the transcripts indeed lacked the 82 bp
region. From the intensity of the RT-PCR bands the propor-
tion of the shorter transcript ASV(3) was densitometrically
determined to be 30% of the total RYR3 transcripts (Fig. 2).
The relative amount of the two PCR bands should be an
accurate approximation of the relative amount of the RNAs
present in the sample as both templates were ampli¢ed under
identical conditions within the same tube. Sequence analysis
of the cloned PCR products con¢rmed that both bands were
indeed derived from RYR3 transcripts.
The physiological signi¢cance of the ASV(3) transcript re-
mains to be determined as the deletion of the 82 nucleotides of
ASV leads to a frame shift that introduces a stop codon only
10 nucleotides downstream of the splice acceptor site (Fig. 3).
This would therefore lead to a protein lacking 9 out of 10
channel forming transmembrane domains. The truncated
RYR3 ASV(3) protein might however have a regulatory ef-
fect on calcium release by competing for e¡ectors or inhibitors
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Fig. 2. RT-PCR with primers RYR3V11217 and RYR3R11799. Human fetal brain total RNA was reverse transcribed using an oligo-d(T) pri-
mer and subjected to 35 cycles of PCR. PCR products were separated on a 1% agarose gel. The experiment was performed with two independ-
ently synthesized cDNAs (1, 2). M: size standard (1 kb ladder). On the right side of the gel the densitometric pro¢le of lane 2 is shown. The
molar ratio of the 583 bp band to the 501 bp band is 7:3.
Fig. 3. Nucleotide and amino acid sequence of the human RYR3 in the region of ASV. Only the boundaries of the alternative splice site are
shown. The central part of ASV contains 69 bp and is represented by dots in the ASV(+) sequence. Missing bases in the ASV(3) sequence are
indicated by dashes.
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of full-length RYR3. Table 2 summarizes the analyzed splice
variants in comparison with all published alternative splice
sites of the RYR3 gene.
3.4. Analysis of the RYR3 protein sequence
Translation of the 14 613 bp open reading frame of the
human RYR3 cDNA led to a protein with 4870 amino acids
and a calculated molecular mass of 552 kDa. Like all other
known RYR sequences the human RYR3 contains a sequence
motif of approximately 85 amino acids which is repeated four
times. The positions of this motif are 849^934, 965^1049,
2598^2683, and 2715^2795. The hydrophobic domains MP,
MQ, M1^M10 originally proposed by Zorzato et al. [10] can
also be found in the human RYR3 at positions 2985^3005,
3049^3057, 3836^3852, 3874^3852, 4138^4157, 4198^4223,
4410^4431, 4482^4505, 4632^4653, 4670^4692, 4712^4731,
and 4751^4774. The two domains M3 and M4 are quite di-
vergent from RYR1 and RYR2 sequences but they still con-
tain a high percentage of hydrophobic residues. Recently, a
new protein domain called SPRY was identi¢ed in RYR1 and
certain kinases [23]. Like RYR1 the human RYR3 contains
three of these SPRY domains at positions 657^795, 1084^
1207, and 1324^1475. An ATP/GTP binding site consensus
sequence AIVSSGKT is located at positions 2840^2847. Three
potential calmodulin binding sites can be found at positions
2903^2919, 3471^3489, and 4391^4408.
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Table 2
Alternative splice sites of the RYR3 gene
Name Nucleotide pos. Type Species / ref. Observed in human fetal brain
(% alt. spliced transcripts)
ASI 10 012^10 026 Removal of 15 nucleotides Mink [14] Yes (approx. 50%)
ASII 11 146^11 163 Removal of 18 nucleotides Mink [14] No
ASIII 10 503^10 599 Alternative use of exons A and B (encoding 31
and 32 amino acids respectively)
Mink [14] No
ASIV 13 799^13 800 341 bp intron is not removed and leads to
truncated protein
Mouse [19] No
ASV 11 569^11 650 Removal of 82 nucleotides leads to truncated protein Human Yes (30%)
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